MR-ProADM Biomarker Thresholds for Polytrauma Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack accurate and early tools for diagnosing, prognosing, predicting, and risk-stratifying trauma-related complications in polytrauma patients, particularly sepsis and non-infection related issues like rhabdomyolysis and organ failure, which are critical for personalized treatment strategies.
Innovation Solution
Utilizing mid-regional proadrenomedullin (MR-proADM) levels in patient samples to determine the likelihood of subsequent trauma-related complications, with specific cut-off values for polytrauma patients, enabling early identification of high or low risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If established biomarkers (CRP, PCT, IL-6) and clinical scores (SOFA, qSOFA) are used for sepsis identification, then routine clinical use is achieved, but early and accurate prediction of trauma-related complications remains insufficient
Solution Approach 1:
The patent introduces proADM as a new biomarker parameter that changes earlier and more specifically in response to trauma-related complications compared to existing markers. By measuring proADM levels and comparing them against established thresholds, the system achieves both early detection and accurate prediction, resolving the contradiction between timing and precision.
2Reliability
If multiple biomarkers and clinical scores are monitored, then comprehensive assessment is achieved, but complexity of diagnostic process increases
Solution Approach 1:
The patent positions proADM as a universal biomarker that can assess multiple types of trauma-related complications (sepsis, organ failure, rhabdomyolysis) through a single measurement. This multi-functional approach maintains comprehensive diagnostic reliability while simplifying the overall process by reducing the number of separate tests needed.
3Measurement precision
If proADM levels are determined with specific cut-off values for polytrauma patients, then early risk identification is achieved, but lack of specific reference values for polytrauma subgroup is overcome
Solution Approach 1:
The patent establishes specific cut-off values and reference ranges tailored to the polytrauma patient population, recognizing that this subgroup has distinct physiological responses compared to general ICU patients. By customizing the diagnostic thresholds for this specific group, the system achieves high precision in risk stratification while maintaining adaptability to the unique characteristics of polytrauma patients.
Data Source
AI summary
The invention relates to a method for the diagnosis, prognosis, prediction, risk assessment and/or risk stratification of a subsequent trauma-related complication in a polytrauma patient, comprising providing a sample of said patient, wherein the sample is isolated from the patient after the polytrauma, determining a level of pro-adrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of pro-adrenomedullin (proADM) or fragment(s) thereof correlates with the likelihood of a subsequent trauma-related complication.